All About Multiple Sclerosis

More MS news articles for September 2003

Monoclonal antibody therapy in experimental allergic encephalomyelitis and multiple sclerosis

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12947225&dopt=Abstract

Immunol Res. 2003;28(1):61-78
Zhang X, Hupperts R, De Baets M.
First Affiliated Hospital, Wenzhou Medical College, Wenzhou, P. R. China.

Experimental autoimmune encephalomyelitis (EAE) is a T-cellmediated demyelinating disease of the central nervous system that has been used as an animal model for multiple sclerosis (MS).

Based on the exciting results in EAE, a number of novel immunotherapies employing biotechnological products, rather than conventional immunosuppressants, are being developed for the treatment of MS.

In this review, we delineate the rationale for monoclonal antibody (MAb) therapy in EAE and MS and summarize the various levels at which immune intervention was performed.

For each approach, we discuss the role of MAbs at the level of lymphocyte and cytokine networks, chemokines, and adhesion molecules or their receptors.